ReviewInsights into imaging2021
Emerging role of 18F-FDG PET/CT in Castleman disease: a review.
Review in Insights into imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02817997 (ACCELERATE), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients With Castleman Disease
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Hyperenhancing paravertebral mass in an adolescent: A rare presentation of unicentric Castleman disease.Radiology case reports · 2026Article
- Unicentric Castleman disease of plasma cell type in the adrenal region: a case report and literature review.Frontiers in oncology · 2026Article
- Castleman disease: clinical features, pathology, and treatment outcomes in 12 cases.Frontiers in oncology · 2026Article
- Article
- Castleman's disease in the rheumatological practice.Zeitschrift fur Rheumatologie · 2024Review
- Review
- Abdominal CT findings characteristic of Castleman disease: multi-centre review of 76 adult cases with abdominopelvic nodal involvement.The British journal of radiology · 2024Article
- [Castleman's disease in the rheumatological practice].Zeitschrift fur Rheumatologie · 2024Review
- Primary hepatic Castleman disease.BMJ case reports · 2024Article
- Retroperitoneal Castlemans disease mimicking a liver cancer: a case report.Frontiers in oncology · 2024Article
- Unmet Clinical Needs in the Management of Idiopathic Multicentric Castleman Disease: A Consensus-based Position Paper From an ad hoc Expert Panel.HemaSphere · 2023Article
- Castleman Disease: A Multicenter Case Series from TurkeyTurkish journal of haematology : official journal of Turkish Society of Haematology · 2022Article
- Castleman disease of the pancreas mimicking pancreatic malignancy onWorld journal of gastrointestinal surgery · 2022Article
- A Rare Lymphoproliferative Disease: Castleman DiseaseTurkish journal of haematology : official journal of Turkish Society of Haematology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Castleman disease (CD) describes a group of rare hematologic conditions involving lymphadenopathy with characteristic histopathology and a spectrum of clinical abnormalities. CD is divided into localized or unicentric CD (UCD) and multicentric CD (MCD) by imaging. MCD is further divided based on etiological driver into human herpesvirus-8-associated MCD, POEMS-associated MCD, and idiopathic MCD. There is notable heterogeneity across MCD, but increased level of pro-inflammatory cytokines, particularly interleukin-6, is an established disease driver in a portion of patients. FDG-PET/CT can help determine UCD versus MCD, evaluate for neoplastic conditions that can mimic MCD clinico-pathologically, and monitor therapy responses. CD requires more robust characterization, earlier diagnosis, and an accurate tool for both monitoring and treatment response evaluation; FDG-PET/CT is particularly suited for this. Moving forward, future prospective studies should further characterize the use of FDG-PET/CT in CD and specifically explore the utility of global disease assessment and dual time point imaging.Trial registration ClinicalTrials.gov, NCT02817997, Registered 29 June 2016, https://clinicaltrials.gov/ct2/show/NCT02817997.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.